| Title |
Non-response to (statin) therapy: the importance of distinguishing non-responders from non-adherers in pharmacogenetic studies
|
|---|---|
| Published in |
European Journal of Clinical Pharmacology, December 2015
|
| DOI | 10.1007/s00228-015-1994-9 |
| Pubmed ID | |
| Authors |
S. Trompet, I. Postmus, P. E. Slagboom, B. T. Heijmans, R. A. J. Smit, A. B. Maier, B. M. Buckley, N. Sattar, D. J. Stott, I. Ford, R. G. J. Westendorp, A. J. M. de Craen, J. W. Jukema |
| Abstract |
In pharmacogenetic research, genetic variation in non-responders and high responders is compared with the aim to identify the genetic loci responsible for this variation in response. However, an important question is whether the non-responders are truly biologically non-responsive or actually non-adherent? Therefore, the aim of this study was to describe, within the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER), characteristics of both non-responders and high responders of statin treatment in order to possibly discriminate non-responders from non-adherers. Baseline characteristics of non-responders to statin therapy (≤10 % LDL-C reduction) were compared with those of high responders (>40 % LDL-C reduction) through a linear regression analysis. In addition, pharmacogenetic candidate gene analysis was performed to show the effect of excluding non-responders from the analysis. Non-responders to statin therapy were younger (p = 0.001), more often smoked (p < 0.001), had a higher alcohol consumption (p < 0.001), had lower LDL cholesterol levels (p < 0.001), had a lower prevalence of hypertension (p < 0.001), and had lower cognitive function (p = 0.035) compared to subjects who highly responded to pravastatin treatment. Moreover, excluding non-responders from pharmacogenetic studies yielded more robust results, as standard errors decreased. Our results suggest that non-responders to statin therapy are more likely to actually be non-adherers, since they have more characteristics that are viewed as indicators of high self-perceived health and low disease awareness, possibly making the subjects less adherent to study medication. We suggest that in pharmacogenetic research, extreme non-responders should be excluded to overcome the problem that non-adherence is investigated instead of non-responsiveness. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 3 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 33% |
| Practitioners (doctors, other healthcare professionals) | 1 | 33% |
| Scientists | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 69 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 1% |
| Unknown | 68 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 12 | 17% |
| Researcher | 9 | 13% |
| Student > Master | 9 | 13% |
| Student > Bachelor | 7 | 10% |
| Other | 6 | 9% |
| Other | 15 | 22% |
| Unknown | 11 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 25 | 36% |
| Biochemistry, Genetics and Molecular Biology | 6 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 7% |
| Nursing and Health Professions | 4 | 6% |
| Agricultural and Biological Sciences | 3 | 4% |
| Other | 9 | 13% |
| Unknown | 17 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 May 2016.
All research outputs
#14,243,242
of 22,836,570 outputs
Outputs from European Journal of Clinical Pharmacology
#1,948
of 2,558 outputs
Outputs of similar age
#203,685
of 388,809 outputs
Outputs of similar age from European Journal of Clinical Pharmacology
#12
of 24 outputs
Altmetric has tracked 22,836,570 research outputs across all sources so far. This one is in the 35th percentile – i.e., 35% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,558 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one is in the 22nd percentile – i.e., 22% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 388,809 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.